Benefits
What the osteoarthritis trials found
A 2020 review pooled 7 randomized trials in 545 people diagnosed with osteoarthritis and found boswellia extracts reduced pain and stiffness and improved joint function compared with control. On a 100-point pain scale the boswellia groups scored about 8 points lower than control. All of this was measured in people with a diagnosed joint condition, not in healthy joints. The trials were small, several were funded by the extract manufacturer, and no cited trial compared boswellia head to head against an NSAID.
5-LOX inhibition (non-NSAID mechanism)
Boswellic acids selectively inhibit 5-lipoxygenase, reducing leukotriene-mediated inflammation. This is a different pathway from NSAIDs, which act on COX. The 5-LOX work is laboratory research, and no cited study compared boswellia with an NSAID for either safety or effectiveness in people.
Inflammatory bowel disease: not covered by the cited evidence
None of the four studies cited on this page looked at inflammatory bowel disease. Older trials in people with Crohn's disease or ulcerative colitis exist elsewhere in the literature, but they are not part of this page's evidence base and were not checked for this audit. Crohn's disease and ulcerative colitis are serious conditions that need medical care, and no supplement should be used in place of prescribed treatment.
Rheumatoid arthritis: not covered by the cited evidence
No study cited on this page enrolled people with rheumatoid arthritis. All four references are osteoarthritis studies, which is a different condition with a different cause. Nothing here supports taking boswellia for rheumatoid arthritis or alongside prescribed rheumatoid arthritis medicines.
Anti-inflammatory and antioxidant
Beyond 5-LOX inhibition, boswellic acids reduce NF-κB activation and other inflammatory pathways. These are findings from cell and laboratory work, not effects measured in people. The only human evidence cited on this page is in osteoarthritis.
AKBA standardization matters significantly
Generic boswellia extracts vary from 3% to 30%+ AKBA content. Quality branded forms standardize to higher AKBA. No cited study compared a high-AKBA extract with a low-AKBA one, so how much this changes results in people is unknown. The head-to-head trial on this page (60 people, 90 days) compared two branded extracts, 5-Loxin and Aflapin, against each other and against placebo, not branded against generic.
Tolerability in the trials so far
Boswellia was generally well tolerated in the cited trials, which enrolled 30 to 75 people each and ran up to 90 days. Because those groups were small and short, uncommon or slow-developing side effects could easily have been missed, and no cited study tested use beyond three months.
Mechanism of action
5-LOX selective inhibition
AKBA non-competitively inhibits 5-lipoxygenase with IC50 values in the low micromolar range, preventing conversion of arachidonic acid to 5-HPETE and subsequently to LTA4 and pro-inflammatory leukotrienes (LTB4, LTC4, LTD4). This pathway is distinct from and complementary to COX inhibition by NSAIDs.
MMP-3 matrix metalloprotease inhibition
AKBA inhibits matrix metalloprotease-3 (MMP-3, stromelysin), the enzyme responsible for degrading articular cartilage collagen and proteoglycans. This is laboratory work on isolated enzymes. No study cited on this page measured cartilage or joint-space changes in people.
NF-κB and cytokine modulation
Boswellic acids inhibit IκB kinase (IKK) activity, preventing NF-κB nuclear translocation and downstream expression of TNF-α, IL-1β, IL-6, and other pro-inflammatory cytokines. These findings come from cell and laboratory studies rather than from measurements taken in people.
Clinical trials
Systematic review and meta-analysis of 7 randomized controlled trials of Boswellia serrata and its extracts in people diagnosed with osteoarthritis. Outcomes: pain (VAS and WOMAC), stiffness, physical function and the Lequesne index. (Yu et al. 2020, BMC Complementary Medicine and Therapies, PMID 32680575)
545 people with diagnosed osteoarthritis, pooled across 7 randomized trials.
Across 7 trials in 545 people with diagnosed osteoarthritis, boswellia reduced pain, stiffness and difficulty with everyday movement compared with control. On a 100-point pain scale the boswellia groups scored about 8 points lower than control (95 percent confidence interval 5 to 11 points), with similar improvements in WOMAC pain, stiffness and function and in the Lequesne index. The review authors concluded boswellia may be an effective and safe option for people with osteoarthritis. Limits: the individual trials were small, several were run and funded by companies selling the extract, and about 4 weeks of use was needed before differences appeared. This says nothing about people who do not have osteoarthritis.
A reported trial of a Boswellia serrata gum resin extract (H15, 1,200 mg three times daily, roughly three times the highest daily amount described anywhere else on this page) against the prescription drug sulfasalazine (3,000 mg a day) in 102 people with active Crohn's disease over 8 weeks. Outcome: Crohn's Disease Activity Index. This study is not one of the four references cited on this page. (Z Gastroenterol)
102 patients with active Crohn's disease. 8-week intervention.
This study is not among the references cited on this page, so its numbers could not be checked and should not be treated as verified. It was a single study in people with an active diagnosed disease who would otherwise be on prescription treatment, with no placebo group. Crohn's disease requires medical care, and boswellia is a food supplement, not a treatment for it. Nothing in this trial applies to a healthy person.
A single small report of Boswellia serrata gum resin (300 mg three times daily) versus placebo in 40 people with diagnosed bronchial asthma over 6 weeks. This study is not among the four references cited on this page and was not verified for this audit. (Eur J Med Res)
40 patients with bronchial asthma. 6-week intervention.
None of this page's four cited references measured breathing or asthma at all; every one of them studied osteoarthritis. With 40 people, one short study and no replication in the cited evidence, this is not a basis for using boswellia for asthma. Asthma is a serious medical condition that needs prescribed treatment, and no supplement should be used in place of it.